This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Jun;46(2):101-102.

doi: 10.4997/JRCPE.2016.208.

Should ReSPonD change falls prevention in Parkinson's disease?

J L Taylor¹, D Sumakadas

Affiliations

PMID: 27929574
DOI: 10.4997/JRCPE.2016.208

Comment

Should ReSPonD change falls prevention in Parkinson's disease?

J L Taylor et al. J R Coll Physicians Edinb. 2016 Jun.

. 2016 Jun;46(2):101-102.

doi: 10.4997/JRCPE.2016.208.

Authors

J L Taylor¹, D Sumakadas

Affiliation

¹ D Sumukadas, Department of Medicine for the Elderly, Ninewells Hospital, Dundee, UK, E-mail d.sumukadas@nhs.net.

PMID: 27929574
DOI: 10.4997/JRCPE.2016.208

No abstract available

PubMed Disclaimer

Comment on

Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.
Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JC, Whone AL, Ben-Shlomo Y. Henderson EJ, et al. Lancet Neurol. 2016 Mar;15(3):249-58. doi: 10.1016/S1474-4422(15)00389-0. Epub 2016 Jan 13. Lancet Neurol. 2016. PMID: 26795874 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information